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A DISSERTATION ON “NONALCOHOLIC FATTY LIVER DISEASE 
IN TYPE 2 DIABETES MELLITUS - AN INDEPENDENT PREDICTOR 
FOR MACROANGIOPATHY AND MICROANGIOPATHY” 
 
INTRODUCTION 
Nonalcoholic fatty liver disease is a condition in which there is collection of fat 
in liver cells mainly triglycerides. Nonalcoholic fatty liver disease is a condition 
most often present in association with Obesity. Nonalcoholic fatty liver disease 
has a strong association with glucose intolerance, insulin resistance, type 2 
diabetes mellitus, either with or without obesity. In Indian population   the 
prevalence of this disease is 15to 20 %, whereas the prevalence among diabetes 
population is more than two fold higher (50 to 75%). There is very strong 
association between nonalcoholic fatty liver disease and type 2 diabetes mellitus 
especially in obese individuals. .  Hyperlipidemia is a risk factor for the 
development of nonalcoholic fatty liver disease. The incidence of non-alcoholic 
fatty liver disease is higher in the diabetic population which may act as a 
predictor for diagnosis of micro and macrovasuclar disease .The micro and 
macrovasuclar disease have a great impact on economy of the patient. 
 
 
AIM OF THE STUDY: 
1. To clarify the clinical characteristics of type 2 diabetic patients with 
non-alcoholic fatty liver disease (NAFLD) 
 
2. To assess whether nonalcoholic fatty liver disease is related to diabetic 
micro and macroangiopathy. 
 
METHODS AND MATERIALS: 
              This was an observational study done in Government Royapettah Hospital. 
The study recruited 100 patients who were admitted in the department of medicine 
and who attended diabetology department as out-patients. Those who fulfilled the 
inclusion and exclusion criteria were included in the study. In patients with type 2 
Diabetes Mellitus, Fasting & postprandial glucose, lipid profile, liver function test 
with enzymes, Ultrasonogram, Urine spot albumin creatinine ratio, ECG, Carotid 
Doppler for Carotid Intimal Thickness, Ankle brachial index by Oscillometric 
method, urea, and creatinine will be done after obtaining written informed consent 
and the findings correlated to find out whether NAFLD is an independent indicator 
of angiopathy in these patients. 
 
 
OBSERVATION AND RESULTS: 
                 Out of 100 patients with diabetes 24 had retinopathy, 33 had 
peripheral arterial disease, 18had peripheral neuropathy, 12 patients had 
cerebrovascular accident, 30 had ischemic heart disease, 31 patients are in grade 
2 diabetic nephropathy, 1 patient is in grade 3 diabetic nephropathy and 1 
patient is in grade 4 diabetic nephropathy. Out of 40 patients with NAFLD 17 
had retinopathy, 18 had peripheral neuropathy, 18 had ischemic heart disease, 
10 had cerebrovascular accident. Among NAFLD patients with peripheral 
arterial disease 11 had mild disease 2 had moderate disease 1 had severe 
disease. Among NAFLD patients with diabetic nephropathy 29 patients are in 
grade 1 diabetic nephropathy, 11 patients are in grade 2diabetic nephropathy 
and there is no patient in grade 3 and grade 4nephropathy.the mean carotid 
intimal medial thickness is high among NAFLD group when compared with 
that of no NAFLD group (.789 Vs 0.698) . The prevalence of retinopathy ( 17 
Vs  7), cerebrovascular accident ( 10 Vs 2), ischemic heart disease ( 18 Vs 12 ), 
peripheral neuropathy ( 18 Vs 0) is high among NAFLD group when compared 
to that of no NAFLD group all of which are statistically significant. The patients 
with NAFLD group had high BMI, high cholesterol, high blood pressure. 
 
 
 
CONCLUSION: 
 The study concluded that the diabetic patients with nonalcoholic liver disease 
have high prevalence of ischemic heart disease, diabetic retinopathy, diabetic 
peripheral neuropathy, cerebrovascular accident and have increased carotid 
intimal medial thickness. The diabetic patients with nonalcoholic liver disease 
did not  have any relation with diabetic nephropathy and peripheral arterial 
disease. The patients with NAFLD group had high BMI, high cholesterol, high 
blood pressure (both systolic and diastolic) high triglyceride levels. 
 
Thus NAFLD in type 2 diabetes mellitus independently predicts of diabetic 
microangiopathy and diabetic macroangiopathy the characteristics of 
NAFLD in type 2 diabetes mellitus are studied. 
Key words: nonalcoholic fatty liver disease, Type 2 diabetes mellitus, diabetic 
macroangiopathy, coronary heart disease. 
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INTRODUCTION 
 Nonalcoholic fatty liver disease is a condition in which there is collection of fat 
in liver cells mainly triglycerides. Nonalcoholic fatty liver disease is a condition 
most often present in association with Obesity.   Nonalcoholic fatty liver disease 
has a strong association with glucose intolerance, insulin resistance, type 2 
diabetes mellitus, either with or without obesity. In Indian population   the 
prevalence of this disease is 15to 20 %, whereas the prevalence among diabetes 
population is more than two fold higher (50 to 75%). 
In upto 75 % of patients, nonalcoholic steatohepatitis may have insulin 
resistance which may be evident as acanthosis nigricans, diabetes mellitus, 
impaired glucose tolerance .The risk of nonalcoholic steatohepatitis is more 
than twofold higher in diabetic population when compared to that of non -
diabetic individuals.  The risk of cardiovascular disease is significantly 
increased when a patient with diabetes has nonalcoholic fatty liver disease. 
There is very strong association between nonalcoholic fatty liver disease and 
type 2 diabetes mellitus especially in obese individuals. Lean individuals also 
have a very good relationship between   nonalcoholic fatty liver disease and 
insulin resistance. The diagnosis of nonalcoholic fatty liver disease requires a 
high degree of suspicion in diabetic population, because of the early progress to 
nonalcoholic steatohepatitis and cirrhosis.  Hyperlipidemia is a risk factor for 
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the development of nonalcoholic fatty liver disease .A study showed an 
incidence of nonalcoholic fatty liver disease was 60% in patients with 
hyperlipidemia. Another study with living liver donors showed that 
hyperlipidemia was associated with more than 2 fold risk of steatosis. 
The risk factors for nonalcoholic fatty liver disease  are  morbid obesity, type 2 
diabetes mellitus, older age (>50 years) ,insulin resistance, and hyperlipidemia. 
Nonalcoholic fatty liver disease has been associated with many conditions 
which has mitochondrial injury as a key pathogenic mechanism. The hepatic 
component of  Syndrome X is nonalcoholic fatty liver disease. The severity of 
nonalcoholic fatty liver disease increases with increasing number of 
components of Syndrome X namely, systemic hypertension, obesity, glucose 
intolerance and hyperlipidemia. 
 
 The incidence of non-alcoholic fatty liver disease is higher in the diabetic 
population which may act as a predictor for diagnosis of micro and 
macrovasuclar disease .The micro and macrovasuclar disease have a great 
impact on economy of the patient. 
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Review of literature 
 
NONALCOHOLIC FATTY LIVER DISEASE 
                                   Nonalcoholic fatty liver disease was first described in the 
1950s when fatty liver was present in a group of obese patients. Nonalcoholic 
steatohepatitis is part of nonalcoholic fatty liver disease which consist of fatty 
liver, nonalcoholic steatohepatitis, and nonalcoholic fatty liver disease -
associated cirrhosis.  
In 1980 at the Mayo Clinic, Ludwig and colleagues described 20 obese, 
diabetic, nonalcoholic patients who had same findings on liver biopsy to that of 
patients with alcoholic liver disease 
[1]
. Following this observation the term 
nonalcoholic steatohepatitis was introduced for the first time. 3% of the general 
population were thought to have nonalcoholic steatohepatitis. Many patients 
who were previously identified as "cryptogenic" cirrhosis, in fact had liver 
disease due to nonalcoholic steatohepatitis.  There will be a resolution of the 
steatosis once patients become catabolic because of cirrhosis.  
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DEFINITION 
―The definition of nonalcoholic fatty liver disease (NAFLD) requires that 
(a) There is evidence of hepatic steatosis, either by imaging or by histology and 
 (b) There are no causes for secondary hepatic fat accumulation such as 
significant alcohol consumption, use of steatogenic medication or hereditary 
disorders‘‘ . 
 
Figure 1show spectrum of nonalcoholic liver disease. 
 
Nonalcoholic fatty liver disease  
           ―Defined as fat exceeding 5–10% of weight in biopsy specimens‖. 
It also includes the term nonalcoholic steatohepatitis. 
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NONALCOHOLIC STEOTOHEPATITIS:  
                                This nonalcoholic fatty liver disease will have ―ballooned 
hepatocytes, inflammation, necroapoptosis (cell death), which is followed by 
fibrosis‖. This process usually begins around the central vein, which may lead 
to cirrhosis.  
 
Non-nonalcoholic steatohepatitis fatty liver (NNFL):  
                        Defined as ―Nonalcoholic fatty infiltration with no or minimal 
inflammation, and no fibrosis‖. (Simple steatosis, Nonalcoholic fatty liver 
(NAFL), pure steatosis, bland steatosis.) 
This form of fatty liver is more stable over time. 
 
“Primary” NONALCOHOLIC FATTY LIVER DISEASE   or NON 
ALCOHOLIC STEATOHEPATITIS: 
―Typical nonalcoholic fatty liver disease or nonalcoholic steatohepatitis is 
associated with central obesity and often type 2 diabetes mellitus but without a 
specific, additional aetiology‖. 
 
―The likelihood that many cases of ―secondary‖ nonalcoholic fatty liver disease 
or nonalcoholic steatohepatitis represent unrecognized or exacerbated ―primary‖ 
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nonalcoholic fatty liver disease or nonalcoholic steatohepatitis makes the term 
less useful‖. 
 
“Secondary” NONALCOHOLIC FATTY LIVER DISEASE or NON 
ALCOHOLIC STEOTOHEPATITIS: 
 “Nonalcoholic fatty liver disease or nonalcoholic steatohepatitis associated 
with a specific, non-alcohol-related problem such as a drug- or toxin-induced 
cause‖ 
 
Toxin-associated steatohepatitis (TASH):  
                                           ―Nonalcoholic fatty liver disease or nonalcoholic 
steatohepatitis associated with a specific toxin or medication. Toxins implicated 
to date include petrochemical exposure in the oil industry and severe vinyl 
chloride exposure, methotrexate and tamoxifen‖. 
 
“Presumed” NONALCOHOLIC STEATOHEPATITIS or NONALCOHOLIC 
FATTY LIVER DISEASE:  
                                     ―Nonalcoholic fatty liver disease  or nonalcoholic 
steatohepatitis based on abnormal liver enzymes, negative viral studies, and 
echogenic or ‗bright‘ liver on ultrasonography consistent with fatty infiltration‖. 
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EPIDEMIOLOGY OF NONALCOHOLIC FATTY LIVER DISEASE 
 
Figure 2 
 
Fig.2 shows the prevalence of nonalcoholic liver disease. 
                     
            The prevalence of nonalcoholic fatty liver disease was not known. 
Different studies were conducted throughout the world, each one of them are 
showing different prevalence rate. The prevalence of nonalcoholic fatty liver 
disease found by magnetic spectroscopy in Dallas study was 31% 
[2]
.  
 
There was another study which was conducted in large population of 15,700 
adults which showed the prevalence of nonalcoholic fatty liver disease was10% 
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to 24%. Obese individuals ranks first in the prevalence rate 
[3,4, 5]
. Prevalence 
rate in obese patients who are not drinking was 76%. The name of this large 
study was the National Health and Nutrition Examination Survey 
[6]
. Most of the 
patients with nonalcoholic fatty liver disease are in the age group of 40 to 60 
years 
[7]
. 
Figure 3 
 
 Fig.3 shows the worldwide prevalence of nonalcoholic liver disease. 
 
In early studies it was found that the prevalence of nonalcoholic liver disease 
was high in females. In subsequent studies it was shown that the prevalence is 
the same in both male and female. 
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The prevalence of nonalcoholic fatty liver disease varies with the ethnicity. The 
highest prevalence was found in Hispanics which was about (45%) of non-
alcoholic fatty liver disease 
[2]
. The prevalence of nonalcoholic fatty liver 
disease among white individual was 33% and among African Americans was 
24% 
[8]
 .The reason for difference in the disparity in different ethnic group was 
not known. The nonalcoholic fatty liver disease can occur as a familial cluster 
[9]
. 
Figure 4 
 
Fig.4 shows the prevalence of nonalcoholic liver disease across the world. 
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AETIOLOGY 
Table 1 
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Table 1 shows the aetiology of nonalcoholic liver disease. 
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“Adult Treatment Panel III clinical features of the metabolic syndrome” 
 
 
 
Figure 5 
 
 
 
Fig.5 shows the features of metabolic syndrome. 
 
 
 
PATHOGENESIS 
THE “TWO-HIT HYPOTHESIS,” 
The proposal for ―two-hit hypothesis,‖ was first given by Day and James [9] in 
1998. 
“First hepatic insult” 
Steatosis is the result of altered fatty acid metabolism. Steatosis is associated 
with several altered signalling pathways and cellular adaptations which render   
liver cells susceptible to a ―second hit.‖ 
24 
 
 
“The second insult”  
The genetic disruption and disruption in the environment plays as the second 
insult. Because of the second insult there will be hepatocyte inflammation 
followed by hepatocyte necrosis which results in the activation the fibrogenic 
cascade, which leads to  fibrosis and then the cirrhosis. 
Figure 6 
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Fig.6 shows ―The two hit hypothesis”. 
The hallmark feature of nonalcoholic fatty liver disease is the steatosis of liver. 
The free fatty acid in the liver was first oxidized by mitochondria, which is then 
esterified into TGL. Phospholipids and cholesteryl esters are synthesised from 
the triglycerides and which is then secreted from the liver as VLDL cholesterol.  
Fatty acid metabolism is under the strict control of hormones like insulin, 
growth hormone, glucagon and catecholamine. There is triglyceride 
accumulation in the liver cell when fatty acid metabolism shifts from 
disintegration to synthesis. Whenever there is excess of free fatty acid there will 
be a shift. The excess fatty acid can be obtained either from intestine or from the 
adipose tissue. The shift usually occurs when the amount of free fatty acid 
supplied to the liver is more than the need for oxidation and the formation of 
cholesteryl esters and phospholipid. Accumulation of triglycerides usually 
occurs in the liver when the rate of lipoprotein synthesis decreases or when the 
liver is not able remove the lipids. 
HYPERINSULINEMIA AND INSULIN RESISTANCE 
The pathogenic mechanism in individuals  with nonalcoholic fatty liver disease 
are insulin resistance and hyperinsulinemia. The insulin resistance and 
hyperinsulinemia play a key role in the pathogenesis of fatty liver in even thin 
individuals . 
[10, 11, 12]  . 
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HISTOLOGY OF OBESE PATIENTS 
Figure 7 
 
 Fig.7 shows the histology of obese patients. Normal histology was seen in 9% 
of individuals .1–2% of individuals had unidentified cirrhosis. Steatosis was 
present in 90% of the cases. Only one third cases with steatosis had met the 
criteria for nonalcoholic steatohepatitis. There was varying degrees of fibrosis 
in nonalcoholic steatohepatitis patients which was upto 40%. 
 
                               The insulin signalling pathway was disturbed by several 
important molecule like Tumour necrosis factor-α (TNF-α ), free fatty acid, 
leptin, and, membrane glycoprotein PC-1which were present in obesity and 
hyperinsulinemia .The  release of free fatty acid  by insulin-resistant adipocytes 
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is abnormal .The insulin resistant adipocytes are present in diabetes and obesity. 
In diabetes there will be hepatic insulin resistance because of decreased 
signalling by insulin receptor substrate-1 because of increased free fatty acid 
[13, 
14]
. There will be decreased disposal of free fatty acid in Insulin resistance and 
hyperinsulinemic state which leads to fatty liver. 
Figure 8 
 
Fig.8 shows the HOMA2 calculator used for calculating insulin resistance. 
 
                        The synthesis of fatty acid   is stimulated by insulin in the liver. 
β-Oxidation of  free fatty acid which occurs in mitochondria  is down regulated 
by insulin .  The release of triglycerides from the liver is blocked by insulin by 
increasing VLDL and apolipoprotein B-100 concentration in the liver cells 
[14, 15, 
16]
.  
Exocytosis of very low density lipoprotein containing vesicles is blocked by 
insulin. Hepatic triglyceride accumulation occurs in individuals with 
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nonalcoholic steatohepatitis because of reduced synthesis of  hepatic  
apolipoprotein B-100
[17]
. 
Figure 9 
 
Fig.9 shows formulas used in calculation of insulin resistance. 
Figure 10 
 
Fig.10 shows pathogenesis of nonalcoholic liver disease. 
INSULIN RESISTANCE 
Adipocytes secrete a number of mediators  like adiponectin, leptin and TNF-α 
which are involved in the pathogenesis of insulin resistance in nonalcoholic 
fatty liver disease
[18]
 .There will be interference in the insulin signalling by 
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TNF-α. This is done by down regulation of IRS-1 signal which acts through 
serine phosphorylation. The insulin resistance which is present in the obese 
individual is mediated by Jun N-terminal kinase (JNK). The free fatty acid 
activates the nuclear factor – κβ/ inhibitor kappa-β kinase (IKK-β) which results 
in decreased liver insulin sensitivity 
[19, 20]
. The activation of this pathway results 
in increased production of inflammatory cytokines such as TNF-α and 
interleukin (IL)-6
[21, 22, 23]
. 
Activation of the ―inhibitor kappa-β kinase (IKK-β)/nuclear factor kappa β (NF-
κβ)‖ pathway by free fatty acid may have a role in decreased liver insulin 
sensitivity. 
ADIPONECTIN: 
From the adipose tissue mainly from visceral, Adiponectin a cytokine which is 
a peptide is secreted. Adiponectin is in inverse proportion to the body weight 
and the body mass index 
[24]
.  The TNF-α is inhibited by adiponectin. 
Adiponectin supresses both plasma and hepatic TNF-α concentration.  In insulin 
resistance, metabolic syndrome, diabetes mellitus, and obesity, the serum level 
of adiponectin is low. 
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Figure 11 
 
Fig.11 shows the role of cytokines in the pathogenesis of nonalcoholic liver 
disease. 
           Adiponectin will increase liver fatty acid metabolism, improves liver 
insulin resistance and also reduces liver triglyceride level which probably gives 
adiponectin a role as a therapeutic agent. 
LEPTIN: 
Adipocytes secrete a hormone called Leptin which is involved in controlling    
satiety (food intake). Maintaining the energy regulation is also under the control 
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of leptin. In insulin signalling, leptin has a role. The metabolism of glucose in 
peripheral tissue is under strict control of leptin.  The partition of lipid between 
synthesis of triglyceride and mitochondrial β-oxidation is also under the control 
of leptin 
[27]
.   
Leptin-deficient (ob/ob) mice had severe fatty liver and nonalcoholic 
steatohepatitis 
[25]
.  In humans obesity is the result of resistance to leptin. There 
is negative impact on signalling of insulin whenever there is increased leptin 
level. In obesity there will be long standing hyperinsulinemia which results in 
fatty liver. Serum leptin levels in individuals with nonalcoholic steatohepatitis 
correlate with the severe  nature of  fatty liver 
[26]
. 
Adipocytokines and their effect on inflammation and insulin action: 
                                          The important factors involved in the development of 
fatty liver are increased insulin levels and insulin resistance. But we lack 
information about the subsequent insults which cause the progression from fatty 
liver to nonalcoholic steatohepatitis and nonalcoholic cirrhosis. There is a 
chronic oxidative stress because of activation of the microsomal enzyme, 
CYP2E1 and increased production of reactive oxygen species from the 
mitochondria 
[28]
.  
The central pathogenic mechanism involved in the development of nonalcoholic 
fatty liver disease is lipid peroxidation. The increased amount of free fatty acid 
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in the blood is directly toxic to the liver cells and increased free fatty acid 
results in destabilization of lysosomes. The TNF-α is stimulated by increased 
free fatty acid 
[29]
.  
Upregulation   of cytochrome P450 isoenzymes occurs with increased free fatty 
acid levels, which results in increased production reactive oxygen species and 
there will be peroxidation of lipid.  Peroxisomal proliferator-activated receptor-
α (PPAR-α) is upregulated due to the raised intracellular levels of free fatty 
acid. PPAR-α upregulation results in oxidation of fatty acid and its removal.  
Upregulation of   PPAR-α result in increased oxidative free radicals formation 
from the derivatives of dicarboxylic acid. The affected individuals are prone to 
development of malignancy due to increased PPAR-α activation. The cell 
membranes are injured by the direct toxic effect of free fatty acid.  
 There is formation of a toxic compound namely fatty acid ethyl ether from free 
fatty acid. There is impairment in the function of mitochondria because of  free 
fatty acid .The  mechanisms which are  protective  against free fatty acid 
induced hepatotoxicity is lost when there  is disruption of the  function of 
mitochondria. 
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BACTERIAL ENDOTOXIN AND NONALCOHOLIC FATTY LIVER 
DISEASE 
Bacterial endotoxin results in the development of nonalcoholic fatty liver 
disease. Nonalcoholic steatohepatitis is believed to develop from portal 
endotoxemia which occurs as a result of 
 
jejunoileal bypass surgery. The risk of 
nonalcoholic steatohepatitis after surgery can be reduced by antibiotics. 
MITOCHONDRIAL CHANGES AND NONALCOHOLIC FATTY 
LIVER DISEASE.    
 The pathogenic processes involved in the formation of nonalcoholic fatty liver 
are altered liver energy metabolism and changes in the mitochondria. In 
nonalcoholic fatty liver disease there is increased free radical formation from 
the mitochondria and there is decrease in function of the respiratory chain in the 
mitochondria. Body mass index, TNF-α level,  insulin resistance correlate with 
the changes in mitochondria 
[31, 32]
.  
Uncoupling protein (UCP-2) present in the mitochondrial inner membrane is 
increased in Ob/ob mice. This protein causes leak in the proton, uncoupling 
ATP synthesis, and regulation of reactive oxygen species production. It also 
makes the fatty liver cells susceptible to the metabolic stress. The replacement 
of ATP in the ATP stores after its usage is reduced in nonalcoholic fatty liver 
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disease. The ATP stores are reduced due to structural changes in the 
mitochondria. 
Mitochondria in patients with nonalcoholic fatty liver disease shows crystalline 
inclusions and their size is large 
[33]
 .Mitochondria assumes these changes as a 
result of oxidative process and it is an adaptive change. The mitochondrial 
changes which are present in nonalcoholic fatty liver disease are same as that in 
Wilson‘s disease and alcoholic liver disease. 
When the nonalcoholic fatty liver disease is advanced, histological features 
suggestive of fibrosis are present. In liver sub endothelial space named as space 
of Disse contains stellate cells. When the stellate cells get activated it results in 
the proliferation and deposition of extracellular matrix mainly collagen type 3 
and type 1. 
The presence of growth factors, oxidative process, changes in extracellular 
matrix, inflammatory cytokines and angiotensin activates the liver stellate cells. 
In nonalcoholic fatty liver disease TGF- β production from the liver occurs as a 
result of peroxidation of lipids. The stellate cells in the liver are activated by 
TGF-β.The stimulus for the proliferation of stellate cells comes from the 
endothelium, leucocyte and kupffer cells by the release of TGF-β and PDGF 
[34]
.The release of connective tissue growth factor is stimulated by 
hyperglycemia and increased insulin levels, which is involved in the process of 
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fibrosis in non-alcoholic fatty liver disease 
[35]
. The process of fibrosis in non-
alcoholic fatty liver disease is perpetuated by leptin. Leptin stimulates 
sinusoidal endothelium and liver kupffer cells to produce TGF-β [36]. 
Nonalcoholic liver disease - a “multi-hit” process: 
 Pathogenesis of nonalcoholic fatty liver disease is a multi-hit process. Increased 
insulin levels and resistance to insulin results in fatty liver which is the first hit. 
The inflammatory process and the process of fibrosis which occurs after the 
formation of fatty liver involves series of mechanism. 
1. Activation of liver kupffer cells 
2. Peroxidation of lipids in the mitochondria 
3. Oxidative damage to the mitochondria 
4. Altered function in the mitochondria 
5. Alteration in the cytokine levels 
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Figure 12 
 
Fig.12 shows the ―multi hit hypothesis of nonalcoholic fatty liver disease‖. 
THE ―MULTI-HIT‖ HYPOTHESIS FOR   
NONALCOHOLIC STEATOHEPATITIS  
The mice model which is deficit in S- adenosyl methionine will have severe 
form of fatty liver disease 
[37]
. The increased glucose levels, increased insulin 
levels, resistance to insulin, increased body weight and fatty liver are produced 
by defects in the cholecystokinin –A receptor. This has been studied in a fatty 
rat model- ―Otsuka-Long-Evans-Tokushima‖ [38]. The rats which are fed on high 
fat diet developed resistance to insulin, increased TNF-α levels, elevated 
oxidative process, lesions in the mitochondria and they will develop fibrosis at 
earlier age 
[39]
. 
 
37 
 
Figure 13 
 
Fig.13 shows the pathogenesis of nonalcoholic fatty liver disease. 
CLINICAL, LABORATORY, AND IMAGING FEATURES  
The diagnosis of nonalcoholic fatty liver disease is mostly incidental. This is 
because of abnormal elevation of liver enzymes or hepatomegaly in screening.   
The patients with nonalcoholic fatty liver disease are asymptomatic.                         
The symptoms of nonalcoholic fatty liver disease are  
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1. Vague pain in the upper right quadrant 
2. Malaise 
3. Fatigue 
Upto 75% of patients with nonalcoholic fatty liver disease have hepatomegaly. 
It is very often difficult to make out hepatomegaly on physical examination, due 
to their increased body weight. Nonalcoholic fatty liver disease -associated 
cirrhosis will have the features of chronic liver disease like enlargement of 
spleen, spider naevi and abdominal distension. 
Figure 14  
    
    
Fig.14 shows the Clinical and Laboratory Features of Nonalcoholic Fatty 
Liver Disease. 
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In simple fatty liver patients the abnormal liver function tests are found in 50% 
of the individuals. In advanced nonalcoholic fatty liver disease patients the 
abnormal liver function tests are found in 80% of the individuals. The elevation 
of AST and ALT is usually up-to 1.5 to 4 fold, but they never exceed 10 times 
of the normal upper limit. The AST level is usually lower than the ALT level 
which is in contrast to the pattern seen in hepatitis due to alcohol. 
 
The levels of GGTP and ALP are increased in nonalcoholic fatty liver disease.  
The Patients usually have normal level of bilirubin, prothrombin time and 
normal level of albumin. The levels of above marker are altered when the 
patient develops nonalcoholic fatty liver disease associated cirrhosis. Low titres 
of ANA may be found in one -fourth of the patients with nonalcoholic fatty 
liver disease 
[40]
. The patients usually don‘t have HbsAg and AMA [41] .The 
patients must not have anti-HCV antibodies in order to confirm the diagnosis of 
nonalcoholic fatty liver disease. Patient must also have normal levels of α1-
antitrypsin and normal ceruloplasmin levels in serum.  
Nonalcoholic fatty liver disease patients may have elevated levels of iron in 
serum and liver. In nonalcoholic fatty liver disease ferritin level in serum is 
increased in 20 to 50% of the patients. In advanced nonalcoholic fatty liver 
disease ferritin level in serum serves as a marker 
[42]
. The incidence of familial 
hemochromatosis is not increasing in nonalcoholic fatty liver disease. The 
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severity in the histological finding doesn‘t have a relationship with clinical and 
lab measures. 
Whenever we suspect nonalcoholic liver disease, in a patient with abnormally 
raised liver functions we usually order for an imaging. The most commonly 
ordered investigation in this setting is ultrasonogram. The finding in the 
ultrasonogram of the liver which suggests nonalcoholic fatty liver disease is 
increase in echogenicity and the liver appears very ―bright‖. CT scan (spleen is 
higher in density than the fatty liver), and MRI of abdomen (T1 weighted 
imaging fat appears bright) are useful in the diagnosis of nonalcoholic liver 
disease. 
 The sensitivity for the diagnosis of nonalcoholic liver disease by USG and CT 
are 100% and 93% respectively when the liver fat is more than 33% with 
positive predictive value of 60% and 75% respectively 
[43]
.These imaging 
studies are helpful only in the diagnosis of nonalcoholic liver disease, but it 
doesn‘t predict the severity of nonalcoholic liver disease .  
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Figure 15 
 
Fig.15 shows the USG finding in nonalcoholic liver disease -increased echo 
texture. 
Figure 16 
 
Fig.16 shows MRI findings in nonalcoholic fatty liver disease.T1-weighted 
MRI showing “bright liver” 
HISTOPATHOLOGIC FEATURES: 
The histological features of both alcoholic and nonalcoholic fatty liver disease 
are same. The spectrum includes    
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1. Fatty liver-steatosis 
2. Steatohepatitis-fatty liver with inflammation of liver parenchyma with 
accompanying necrosis. 
3. Cirrhosis  
 
Figure 17 
 
Fig.17 shows histological features of nonalcoholic liver disease. 
HISTOLOGIC FEATURES OF FATTY LIVER. 
1. Presence of macrovesicular steatosis (it is present in all the areas of 
hepatic lobule.) 
2. Infiltration of  WBC‘s mainly PMN‘s, lymphocytes are seen. 
3.  The nuclei are studded with glycogen. 
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Figure 18 
 
Fig.18 shows micro and macro vesicular steatosis. 
The advanced stage of nonalcoholic fatty liver disease is nonalcoholic 
steatohepatitis. It is very difficult to distinguish it from alcoholic liver disease 
by histology. Fatty liver is present in most of the patients.  Central zone of the 
liver is affected primarily which then it involves entire liver. The individual‘s 
body mass index correlates with the degree of fatty liver.   
The nonalcoholic liver disease patients will have severe degree of fat deposition 
than alcoholic liver disease 
[44]
. Nonalcoholic steatohepatitis have lobular 
inflammation. Lobular inflammation is manifested by infiltration of   PMNs, 
mononuclear cells and lymphocytes. According  to the severity of nonalcoholic 
fatty liver disease, the degree of inflammation changes. In nonalcoholic fatty 
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liver disease the degree of inflammation is milder when compared to that of 
alcoholic liver disease 
[45]
 
Figure 19 
 
Fig.19 shows Antikeratin 8/18 immunohistochemistry. The arrow 
shows ballooned liver cell are “empty of keratin” 
 
The histological features of nonalcoholic fatty liver disease  
  
1. The nuclei have glycogen inclusions. 
2. The liver cells are ballooned. 
3. Necrosis of liver cell is present. 
4. Mallory Denk bodies are seen.  
5.50% of the individual have iron which is stainable. 
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6. In nonalcoholic steatohepatitis upto 37% to 84% of individuals may have 
fibrosis in periportal, perisinusoidal and pericellular. 
Figure 20 
 
 In fig.20 the arrow shows liver cells with “Mallory Denk bodies” 
                When the patients have ballooning and necrosis of liver cells, the 
prognosis is bad 
[46]
. The fibrosis in perisinusoidal region is very frequently seen 
in adults and it usually in zone 3.In nonalcoholic fatty liver disease, upto 7% to 
16% of individuals have cirrhosis. In nonalcoholic fatty liver disease the morbid 
obese individual has the greatest risk of getting cirrhosis.  When the patient 
develops nonalcoholic fatty liver disease associated cirrhosis, the classical 
feature in the histology of nonalcoholic fatty liver disease is lost which may 
lead us to make the wrong diagnosis of  cryptogenic cirrhosis. 
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Figure 21 
 
Fig.21 shows nonalcoholic steatohepatitis with cirrhosis. 
 
Table 2 
 
Table 2shows the different scales used in the histology of nonalcoholic fatty 
liver disease. 
 
 
DIAGNOSIS  
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      Diagnosis of nonalcoholic fatty liver disease can be established by  
1. Imaging 
2. Histology 
We usually evaluate nonalcoholic fatty liver disease patients because of their 
long term elevation of liver function test with or without liver enlargement. We 
usually need history of the patient, examination, biochemical tests and imaging 
modality to exclude the secondary causes of steatosis.  
Even if the patient doesn‘t have typical findings on imaging, it doesn‘t exclude 
the diagnosis of nonalcoholic fatty liver disease. We should rule out alcoholic 
liver disease first before making the diagnosis of nonalcoholic fatty liver 
disease. It is very difficult to differentiate nonalcoholic fatty liver disease and 
alcoholic liver disease by both clinical and histological methods. So we should 
make the diagnosis of nonalcoholic fatty liver disease only when the patient 
didn‘t take ―significant amount of alcohol - consumption of less than 20 to 40 g 
of alcohol per day‖. 
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Table 3 
 
Table 3 shows investigation employed in nonalcoholic liver disease. 
The Role of Liver Biopsy  
The role of liver biopsy in nonalcoholic fatty liver disease has not been well 
established. The diagnosis of nonalcoholic fatty liver disease is usually made by 
excluding the causes of chronic liver disease by clinical and biochemical 
examination. So it is a diagnosis of exclusion.  
 
Diagnosis of nonalcoholic fatty liver disease is made when ultrasonogram or CT 
shows fatty liver. Most of the individuals with nonalcoholic fatty liver disease 
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usually don‘t undergo liver biopsy, because liver biopsy results are not going to 
change the management of nonalcoholic fatty liver disease. There is no clear cut 
relationship between clinical examination, biochemical tests and histology. 
 
 Some patients with normal liver function test will have advanced disease in 
biopsy. The quantity of ―steatosis, necrosis and fibrosis‖ can be only assessed 
through liver biopsy. The best prognostic marker for nonalcoholic fatty liver 
disease is histology. It is advisable to do liver biopsy in patients who are 
suspected to have advanced form of nonalcoholic fatty liver disease because 
liver biopsy can influence the treatment. 
INDICATION OF LIVER BIOPSY IN NONALCOHOLIC FATTY LIVER 
DISEASE 
[47]
: 
1. Overweight and obese individuals 
2. Abnormal persistent elevation of liver function tests even after good glucose 
control and loss of weight 
3. Advanced age 
4. Metabolic syndrome with multiple components 
5. AST/ALT > 1 
6. Signs and symptoms of portal hypertension 
7. Radiological evidence of fibrosis. 
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The liver biopsy is considered in above patients because the liver biopsy results 
may help us to treat the patient aggressively. It also ensures us to screen the 
patient for the future development of hepatocellular carcinoma and also helps 
the patient to participate in clinical trials. 
DISADVANTAGES OF LIVER BIOPSY: 
1. Costly 
2. Invasive  
3. Small risk of complications like pneumothorax, injury to the kidney, bile duct 
and bleeding manifestations. 
Non-invasive Markers of Fibrosis in nonalcoholic fatty liver disease:   
1. Serum α2-macroglobulin 
2. Apolipoprotein A-1 
3. Haptoglobin 
4. Total bilirubin, and GGTP levels,  
5. Necroinflammatory activity index  
6. Transient elastography (Fibroscan) 
[48]
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7. Serum dehydro epiandrosterone levels 
[49]
 
8. Serum hyaluronic acid levels 
[50] 
9. The Fibro Test [51]  
Table 4 
Table 4 shows the interpretation of results of fibro test.
 
NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE: 
This score is formulated and validated by Angulo 
[52].
 This score uses only 
Clinical and biochemical values. 
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Table 5 
Table 5 shows the parameters used in nonalcoholic fatty liver disease fibrosis 
score. 
NATURAL HISTORY  
Nonalcoholic fatty liver disease is a benign disease .When the patient doesn‘t 
have liver necrosis or fibrosis the prognosis is usually favourable 
[53]
. They have 
only little chance of getting severe form of disease. Liver failure, cirrhosis 
hepatocellular carcinoma can develop in few patients of nonalcoholic fatty liver 
disease. 
            From 2003 to 2008, 215 patients have been studied in 5 retrospective 
studies using paired biopsy of liver 
[54, 55, 56]
. They were followed for a period of 
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1 to 14 years. The progression in the histology of liver (fibrosis) was present in 
the 30 to 40% of individuals with non-alcoholic fatty liver disease. The 
histological course was stable in about 35 to 50% of individuals with non-
alcoholic fatty liver disease. Histology improved in about 15 to 30% of persons 
with non-alcoholic fatty liver disease. There was a variable rate of development 
of fibrosis. There was no correlation between clinical picture and the histology.  
                         There is no reliable marker for the prediction of course of 
nonalcoholic fatty liver disease. A large study with 420 individuals was 
conducted in Minnesota   using definite cases of non-alcoholic fatty liver 
disease 
[57]
. The diagnosis of nonalcoholic fatty liver disease was made in these 
patients using ultrasound. Among them, 3% developed cirrhosis over a period 
of 8 years. The common causes of death in these patients are malignancy, 
coronary artery disease and liver disease in that order. So, nonalcoholic fatty 
liver disease follows an indolent course. There was another study using 130 
individuals with non-alcoholic fatty liver disease over a period of 20 years 
which confirmed the previous conclusions.  
                             The mortality and morbidity were higher in nonalcoholic 
steatohepatitis individuals when compared with the general population. When 
compared with general population, the children with nonalcoholic fatty liver 
disease have decreased survival rate. The natural history of nonalcoholic fatty 
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liver disease can be assessed by the severity of the damage in the liver 
histology.  
In nonalcoholic fatty liver disease   when the patient has only steatosis without 
any signs of inflammation, they usually have a benign course .Upto 16 to 26% 
of patients with nonalcoholic steatohepatitis can progress to liver cirrhosis over 
a period of 20 years. At the time of diagnosis, upto one third of biopsy in 
nonalcoholic steatohepatitis individuals show fibrosis of liver in the advanced 
stage and 16% show established liver cirrhosis.  
            Most of the cases which are previously identified as cryptogenic 
cirrhosis are actually nonalcoholic fatty liver disease associated cirrhosis 
[58, 59, 
and 60]
. In these patients the histological features of nonalcoholic steatohepatitis 
or nonalcoholic fatty liver disease is replaced by plain cirrhosis. Hepatocellular 
carcinoma can develop from nonalcoholic fatty liver disease associated 
cirrhosis. The prevalence of hepatocellular carcinoma in nonalcoholic fatty liver 
disease associated cirrhosis ranges from 0.6 to 3% .In Japanese study it has been 
shown that the cumulative risk of getting hepatocellular carcinoma in non-
alcoholic fatty liver disease patient is as high as 15%. 
Whenever patient develops nonalcoholic fatty liver disease associated cirrhosis 
we should consider liver transplantation in them .However there is a recurrence 
of nonalcoholic fatty liver disease associated cirrhosis in the liver transplanted 
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individuals. The cause of recurrence of nonalcoholic fatty liver disease 
associated cirrhosis in them is not known.  
Figure 21 
 
Fig.21 shows the natural history of nonalcoholic fatty liver disease. 
 
Several numbers of genes have been thought to play a role in the natural history 
of nonalcoholic fatty liver disease and are yet to be revealed. The survival rate 
of patients with nonalcoholic fatty liver disease was higher than that of the 
patient with alcoholic liver disease though they share common histological 
picture. A study compared the outcome of nonalcoholic fatty liver disease 
associated cirrhosis and hepatitis C virus associated cirrhosis 
[61]
. The study 
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revealed the outcome was similar in both groups; however incidence of 
development of hepatocellular carcinoma is low in the first group. 
Table 6 
 
Table 6 shows the risk factors for advanced nonalcoholic fatty liver disease. 
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Figure 22 
  
Fig.22 shows spectrum of NAFLD and its progression. 
TREATMENT  
The therapy which is optimum for the treatment of nonalcoholic liver disease is 
not known. Till now, no randomized control trials have shown any 
improvement in inflammation, steatosis and fibrosis. 
In olden days the treatment for non-alcoholic fatty liver disease emphasised   
1. Reduction in the body weight 
2. Withdrawal of toxin and drugs from the patients. 
3. Control of blood sugar in case of diabetes. 
4. Control of cholesterol levels 
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Figure 23 
 
Fig.23 shows pathogenesis and the management of NAFLD. 
In patients with nonalcoholic fatty liver disease exercise and diet appears to be 
beneficial. Exercise and diet show improvement in imaging and laboratory 
values 
[62, 63, 64 ].
When the loss of weight is sustained by nutritional intensive 
counselling, there is improvement in the histology 
[65]
 .In few studies it was 
shown that weight reduction with orlistat results in improvement of liver 
histology and liver function test 
[66 67]
. Orlistat is a reversible inhibitor of lipases 
from the stomach and the pancreas. 
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Figure 24 
 
Fig.24 shows the dietary plan in patients with nonalcoholic liver disease. 
In few studies it was shown that weight reduction with
 
Bariatric surgery results 
in improvement of liver histology and liver function test 
[68-72].
 It also results in  
1. Maximal loss of weight. 
2. Improvement in the sensitivity of insulin. 
3. Normalization of metabolic parameters which are involved in the           
pathogenic process of nonalcoholic fatty liver disease. 
4. The expression of inflammatory mediators from the liver are reduced. 
 5. Improvement in the histology of liver. 
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Figure 25 
 
Fig.25 shows the modalities employed in the treatment of nonalcoholic fatty 
liver disease. 
The effect of loss of weight achieved by drugs, surgery or exercise was not well 
established in the studies 
[73]
. Though there are no clear cut guidelines to say 
whether weight loss is beneficial or not, it is better to advice weight loss in 
obese patients. It is very difficult to maintain sustainable weight loss. In obese 
individuals rapid weight loss results in nonalcoholic fatty liver disease 
[74]
. The 
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very important thing in loss of weight is the rate at which weight reduction 
occurs. 
Antioxidants  
Vitamin E 
             Vitamin E, is a powerful  antioxidant, which has been used for  
treatment of nonalcoholic fatty liver disease .Vitamin E is a very  well tolerated 
drug., in most of studies it was shown that treatment with vitamin E results in 
the improvement of liver function test, liver imaging and its histology
[75,76]
 
.Vitamin E has  negative effects on cardiovascular system , there should be  
caution in using this drug  in the  treatment of  non-alcoholic fatty  liver 
[77]
.  
Betaine: 
A choline metabolite betaine increases S –adenosylmethione levels and it also 
reduces the oxidative damage in the cell 
[78]
. 
Superoxide dismutase, N-acetylcysteine and ragaglitazar may be used in non- 
alcoholic liver disease, but the human studies are lacking 
[79, 80]
. 
Insulin-Sensitizing Agents: 
The association between non-alcoholic fatty liver disease and increased insulin 
level, resistance to insulin gives a target for therapy with insulin sensitizers. 
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METFORMIN: 
 It is an oral hypoglycemic agent that belongs to the class of a biguanides. 
1. It  reduces the state of hyperinsulinemia 
2. Improves  sensitivity of insulin in liver 
3. Resolves  hepatomegaly and 
4. Resolves liver steatosis in ob/ob mice[81] 
In trials the effect of this drug was not too good 
[82, 83]. 
 THIAZOLIDINEDIONES: 
              It acts through PPAR-α receptors and it has agonistic action over this 
receptor. The liver, muscle and adipose tissue have PPAR-α receptor. PPAR-α 
cause differentiation of cell and reduces the rate of lipolysis and free fatty acid 
release from the adipocytes. Thiazolidinediones increase the sensitivity of 
insulin and   improves disposal of glucose in muscle and reduces glucose output 
from the liver.  Pioglitazone and Rosiglitazone, have lower rates of liver 
toxicity. Both have been studied in different 48-week trials in individuals with 
nonalcoholic steatohepatitis 
[84, 85]
. In both the trails it has been shown that 
treatment with thiazolidinedione‘s was tolerated well. It was associated with 
improvement in sensitivity of   insulin, improvement of liver function test, and 
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improvement in liver histology. The side effects of both TZD‘s are gain in 
weight (4.0% to 7.3%) and increase in adiposity.  
 Iron Reduction:  
                  In nonalcoholic fatty liver disease patients, the levels of ferritin and 
the iron are high in the serum. The elevated level of iron in the liver is believed 
to be involved in the pathogenesis of nonalcoholic fatty liver disease. The 
elevated level of iron in the serum induces inflammation in the liver. Therefore, 
removal of iron from the body is believed to help the patients with nonalcoholic 
fatty liver disease by decreasing the levels of sugar, insulin in the plasma and 
normalizing the liver function test 
[86, 87]
. 
―The relationship between iron and insulin is complex‖ but depletion of iron 
may have the insulin-sparing effect 
[88]
 .It results in enhanced transport of 
glucose in the skeletal muscle. It also reduces the metabolism and the removal 
of insulin from the liver.  
Lipid-Lowering and cytoprotective Agents:  
In some trials the usefulness of UDCA, a cytoprotective drug and gemfibrozil, a 
lipid-lowering agent has been studied with different results. 
         Gemfibrozil may be used in the treatment of nonalcoholic fatty liver 
disease and its treatment showed improvement in biochemical parameters in 
74% of individuals in the treatment group 
[89]
.  In nonalcoholic steatohepatitis 
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treatment with atorvastatin showed improvement in biochemical parameters in a 
small study 
[90]
. 
Ursodeoxycholic acid: 
                          Ursodeoxycholic acid, a cytoprotective agent, used in 
nonalcoholic steatohepatitis showed promising result 
[91]
. The combination of 
vitamin E and ursodeoxycholic acid results in some benefit. 
The fibrosis in nonalcoholic fatty liver disease is induced by the renin-
angiotensin system. Angiotensin-receptor blockers and Angiotensin-converting 
enzyme inhibitors improves the   sensitivity of insulin. Treatment with ARBs 
showed improvement in liver histology. 
Cardiovascular risk and lipid profile are improved by monounsaturated fatty 
acid. Polyunsaturated fatty acid improves liver function test and liver histology. 
In nonalcoholic fatty liver disease, steatosis was improved by L-carnitine. The 
overgrowth of bacteria in the small intestine has been linked with the 
nonalcoholic fatty liver disease. This made us to use pre and probiotics in the 
treatment of non-alcoholic fatty liver disease. The relationship between 
consumption of coffee and nonalcoholic fatty liver disease is inverse. So we 
should recommend our patients to consume coffee at regular intervals. 
Future trends in the treatment of nonalcoholic fatty liver disease   are  
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1. Agents that  inhibit  TNF-α , 
2. Agents that increase  levels  of  adiponectin,  
3. Agents that  alter  levels  of  leptin 
4.  Agents that improve ATP homeostasis in mitochondria.  
Liver Transplantation  
                      Patients with nonalcoholic fatty liver disease with end-stage liver 
disease should be evaluated for liver transplantation. The outcome of liver 
transplantation in this nonalcoholic fatty liver disease is good. The nonalcoholic 
fatty liver disease can recur after liver transplantation 
[92, 93]
. The risk factors for 
de novo or recurrent nonalcoholic fatty liver disease after liver transplantation 
probably are multifactorial and include diabetes mellitus, hypertriglyceridemia, 
glucocorticoid therapy, and obesity.  
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AIMS AND OBJECTIVES 
 
 
AIM OF THE STUDY: 
1. To clarify the characteristics of type 2 diabetic patients with non-
alcoholic fatty liver disease (NAFLD). 
 
2. To assess whether nonalcoholic fatty liver disease is related to diabetic 
micro and macroangiopathy. 
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METHODS AND 
MATERIALS 
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METHODS AND MATERIALS: 
Study group   : Patients with type2 diabetes mellitus who  
                                                    visited the Department Of Internal Medicine                                           
          Study design   : Cross-Sectional study 
          Place of Study    : Govt. Royapettah Hospital 
         Study population                    : 100 
Duration of study    : 6 months 
Conflict of interest  :  Nil. 
METHODOLOGY: 
In patients with type 2 Diabetes Mellitus, Fasting & postprandial glucose, lipid 
profile, liver function test with enzymes, Ultrasonogram, Urine spot albumin 
creatinine ratio, ECG, Carotid Doppler for Carotid Intimal Thickness, Ankle 
brachial index by Oscillometric method, urea, and creatinine will be done after 
obtaining written informed consent and the findings correlated to find out whether 
NAFLD is an independent indicator of angiopathy in these patients. 
The person weight is classified according to the Asian BMI chart as 
underweight, normal weight, overweight, and obese individual. 
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<18.5 Underweight 
18.5 - 23.9 Healthy weight range 
24 - 26.9 Overweight 
>27 Obese 
 
 
 The peripheral arterial disease is diagnosed by using ankle brachial index. The 
ankle brachial index in diabetic patients is measured by oscillometry method. 
The peripheral arterial disease is classified into mild moderate and severe 
disease according to the following ankle brachial index values. 
 
Assessment and definition of diabetic nephropathy was based on the following 
criteria. 
Diabetic nephropathy 
(DN) was staged according to an analysis of the spot urine sample as: 
―DN stage I (normoalbuminuria), albumin/creatinine ratio (ACR) <30 mg/g 
creatinine;  
DN stage II (microalbuminuria): 30 _ACR <300 mg/g creatinine; 
 DN stage III (macroalbuminuria): ACR >300 mg/g creatinine and eGFR >30 
mL/min/1.73m2;  
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DN stage IV: ACR _300 mg/g creatinine and eGFR <30 mL/min/1.73m2‖. 
―eGFR (mL/min/1.73m2)=194×Scr-1.094×Age-0.287×0.739” 
The patients‘ vibration senses are tested with 128 Hz turning fork. The 
peripheral neuropathy in diabetic patients is diagnosed by testing the vibration 
sense and deep tendon reflex. The fundus examination is done with direct 
ophthalmoscope by which diabetic retinopathy is identified. The ischemic heart 
disease is identified using electrocardiogram. The carotid intimal thickness is 
measured using Doppler ultrasound. The cerebrovascular accident is diagnosed 
by those having findings in the CT and those having TIA. 
Inclusion criteria : 
All patients with type 2 diabetes mellitus 
Exclusion criteria : 
1. Excessive alcohol ingestion 
         (Consumption>21 drinks on average per week in men and >14 
drinks on average per week, 1 alcoholic drink =10 grams of alcohol) 
2. Wilson disease 
3. Lipodystrophy 
4. Starvation 
5. Parenteral nutrition 
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6. Medications like amiodarone, methotrexate, tamoxifen, 
corticosteroids valproate, anti-retroviral medicines. 
7. History of viral hepatitis, obesity related surgery 
 
Data collection: 
The data of each patient will be collected on a proforma specially designed for 
this study and which includes demographic details, clinical features, past 
medical history, clinical and Lab values which will be analyzed for statistical 
significance and correlation. 
STATISTICAL ANALYSIS  
Statistical analysis was done to identify significance and correlation between. 
Nonalcoholic fatty liver disease and diabetic micro and macroangiopathy 
Statistical analysis was done using Statistics Products Services Solutions (SPSS 
15) software. Univariate analysis was done with paired t test and Pearson 
product moment correlation coefficient. A chi squared test was used to analyse 
the probability of differences in frequency distributions between the groups and 
p<0.05 was taken to be statistically significant in all calculations. 
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OBSERVATION AND 
RESULTS 
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OBSERVATION AND RESULTS 
PREVALANCE: 
Table.7 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Yes 40 40.0 40.0 40.0 
  No 60 60.0 60.0 100.0 
  Total 100 100.0 100.0   
 
Table.7 shows the percentage of diabetic population having NAFLD. 
                         According to our study the prevalence of nonalcoholic fatty liver 
disease in type 2 diabetes mellitus is 40%.  
Chart.1 
 
Chart.1 shows the percentage of diabetic population having NAFLD 
DIABETIC PATIENTS 
NAFLD
NO NAFLD
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Table . 8 
   NAFLD  Total P value 
    Yes No   0.281 
Sex Male Count 19 22 41 
    % within Sex 46.3% 53.7% 100.0% 
    % within NAFLD  47.5% 36.7% 41.0% 
  Female Count 21 38 59  
    % within Sex 35.6% 64.4% 100.0%  
    % within NAFLD  52.5% 63.3% 59.0%  
Total Count 40 60 100  
  % within Sex 40.0% 60.0% 100.0%  
  % within NAFLD 100.0
% 
100.0
% 
100.0% 
 
 
Table .8 shows the sex distribution in patients with nonalcoholic fatty liver 
disease. 
 
                             Out of 41 male patients with diabetes mellitus 19 had non-
alcoholic fatty liver disease. Out of 59 female patients with diabetes mellitus 21 
had non-alcoholic fatty liver disease with p value of .281which is statistically 
insignificant. So according to our study there is no gender difference in the 
incidence of nonalcoholic fatty liver disease in diabetes population. 
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Chart. 2 
 
Chart.2 shows the sex distribution in patients with nonalcoholic fatty liver 
disease. 
 
Chart.3 
 
Chart.3 shows age distribution among nonalcoholic fatty liver disease. 
 
Out of 40 patients with NAFLD 21 patients are in the age group of 50 to 60 
years of age.  
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Table. 9 
 
    NAFLD Total P value 
    Yes No   
BMI Underweight Count      1 0 1 0.001 
    % within BMI 100.% .0% 100.0% 
    % within NAFLD 2.5% .0% 1.0% 
  Normal Count 6 34 40 
    % within BMI 15.0% 85.0% 100.0% 
    % within NAFLD 15.0% 56.7% 40.0% 
  Over weight Count 22 17 39 
    % within BMI 56.4% 43.6% 100.0% 
    % within NAFLD 55.0% 28.3% 39.0% 
  Obese Count 11 9 20 
    % within BMI 55.0% 45.0% 100.0% 
    % within NAFLD 27.5% 15.0% 20.0% 
Total Count 40 60 100 
  % within BMI 40.0% 60.0% 100.0% 
  % within NAFLD 100.0
% 
100.0
% 
100.0% 
 
Table.9 shows the weight distribution in diabetic patients having NAFLD and 
no NAFLD. 
 
  
                                Out of 100 individual with type 2 diabetes mellitus,1 individual 
was underweight .40 person had normal weight ,39 person had overweight and 
20 individual had obesity. Out 40 individual with NAFLD 1 had underweight,   
6 person had normal weight, 22 person had overweight and 11 individual had 
obesity. So the patients with NAFLD are mostly obese and overweight which is 
statistically significant. (P value -0.001) 
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Chart. 4 
 
Chart 4 shows the weight distribution in diabetic patients having NAFLD and 
no NAFLD. 
                           
DURATION OF DIABETES  
Table.10 
 
NAFLD N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P value 
 
Duration 
of 
Diabetes 
Yes 
40 4.50 2.013 .318 
0.062 
  No 60 3.82 2.087 .269 
   
Table. 10.shows the duration of diabetes in NAFLD and no NAFLD patients. 
The mean duration of diabetes in NAFLD group is 4.5years and the mean 
duration of years in no NAFLD group was 3.82 which is statistically 
insignificant. (P value -0.062) 
NAFLD
NO NAFLD0
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BLOOD PRESSURE   
TABLE.11 
 NAFLD N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P value 
SBP Yes 40 139.95 15.100 2.387 0.006 
  No 60 129.93 18.966 2.449 
DBP Yes 40 88.53 11.602 1.834 0.012 
  No 60 82.95 9.989 1.290 
 Table .11 shows mean blood pressure in diabetic NAFLD patients. 
The mean systolic blood pressure of NAFLD group was 139.95 and that of  no 
NAFLD group was 129.93. The mean diastolic blood pressure of NAFLD group 
was 88.53and that of no NAFLD group was 82.95.So the patients with NAFLD 
have high systolic and diastolic blood pressure which is statistically significant 
(p value -0.006 and 0.012 ) 
 
 
 
 
 
 
 
 
 
 
79 
 
PERIPHERAL ARTERIAL DISEASE 
Table.12 
 
    NAFLD Total P 
value     Yes No   
ABI Normal Count 26 41 67 0 .692 
    % within ABI 38.8% 61.2% 100.0% 
    % within NAFLD 65.0% 68.3% 67.0% 
  Mild Count 11 12 23 
    % within ABI 47.8% 52.2% 100.0% 
    % within NAFLD 27.5% 20.0% 23.0% 
  Moderate Count 2 6 8 
    % within ABI 25.0% 75.0% 100.0% 
    % within NAFLD 5.0% 10.0% 8.0% 
  Severe Count 1 1 2 
    % within ABI 50.0% 50.0% 100.0% 
    % within NAFLD 2.5% 1.7% 2.0% 
Total Count 40 60 100 
  % within ABI 40.0% 60% 100% 
  % within NAFLD 100.0% 100.0% 100.0% 
  
Table.12 shows the ankle brachial index distribution in diabetic patients having 
NAFLD and no NAFLD. 
                          Among 100 diabetic patients 33 patients had peripheral arterial 
disease. Among 33 patients with peripheral arterial disease 23 had mild disease 
8 had moderate disease 2 had severe disease. Among NAFLD patients 11 had 
mild disease 2 had moderate disease 1 had severe disease. Out of 40 patients 
with NAFLD 14 patients had peripheral arterial disease. The prevalence of 
peripheral arterial disease among diabetic patients with NAFLD is not high 
when compared to that of no NAFLD diabetic group (14  vs 19 ) and it is 
statistically insignificant (P value  0.692). 
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Chart.5 
 
 Chart.5 shows the ankle brachial index distribution in diabetic patients having 
NAFLD and no NAFLD. 
 
 
CEREBROVASCULAR ACCIDENT 
 
Table.15  
 
Table.15 shows the CVA distribution in diabetic patients having NAFLD and 
no NAFLD. 
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   NAFLD Total P value 
    Yes No   
CVA Yes Count 10 2 12 0.001 
    % within CVA 83.3% 16.7% 100.0% 
    % within NAFLD  25.0% 3.3% 12.0% 
  No Count 30 58 88 
    % within CVA 34.1% 65.9% 100.0% 
    % within NAFLD 75.0% 96.7% 88.0% 
Total Count 40 60 100 
  % within CVA 40.0% 60.0% 100.0% 
  % within NAFLD 100.0% 100.0% 100.0% 
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Out of 100 patients with diabetes 12 patients had cerebrovascular accident. Out 
of 40 patients with NAFLD 10 had cerebrovascular accident and 30 did not 
have cerebrovascular accident. So prevalence of cerebrovascular accident is 
high among NAFLD diabetic patients when compared to that of no NAFLD  
diabetic group (10 vs 2 ) which is statistically significant (p value -.001)  
 
 
Chart.8 
 
 
Chart.8 shows the CVA distribution in diabetic patients having NAFLD and no 
NAFLD. 
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ISCHEMIC HEART DISEASE  
Table.16 
 
    NAFLD Total P value 
    Yes No   
IHD Yes Count 18 12 30 .008 
    % within IHD 60.0% 40.0% 100.0% 
    % within NAFLD 45.0% 20.0% 30.0% 
  No Count 22 48 70 
    % within IHD 31.4% 68.6% 100.0% 
    % within NAFLD 55.0% 80.0% 70.0% 
Total Count 40 60 100 
  % within IHD 40.0% 60.0% 100.0%  
  % within NAFLD 100.0% 100.0% 100.0%  
Table.16 shows the ischemic heart disease distribution in diabetic patients 
having NAFLD and no NAFLD. 
 
Out of 100 patients with diabetes 30 patients had ischemic heart disease. Out of 
40 patients with NAFLD 18 had ischemic heart disease and 12 did not have 
ischemic heart disease. Out of 30patients with ischemic heart disease 18 had 
NAFLD. So prevalence of ischemic heart disease is high among NAFLD 
diabetic patients when compared to that of no NAFLD  diabetic group( 18 vs 12 
) which is statistically significant (p value -0.008). 
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Chart.9 
 
 
Chart.9 shows the ischemic heart disease distribution in diabetic patients 
having NAFLD and no NAFLD 
 
CAROTID INTIMAL MEDIAL THICKNESS 
 
Table.17 
 
 NAFLD 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
p value 
CIMT Yes 40 .789 .1961 .0310 .010 
   No 60 .698 .1489 .0192 
Table.17 shows the mean carotid intimal medial thickness. 
 
 
The mean carotid intimal medial thickness in NAFLD group is.789 and that of 
no NAFLD group is 0.698. So the intimal medial thickness is high in NAFLD 
group which is statistically significant (P 0.010).  
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RETINOPATHY: 
 
Table.13 
 
 
Table.13 shows the retinopathy distribution in diabetic patients having NAFLD 
and no NAFLD. 
 
 
                 Out of 100 patients with diabetes 24 patients had retinopathy. Out of 
40 patients with NAFLD 17 had retinopathy and 23 did not have retinopathy. So 
prevalence of retinopathy is high among NAFLD diabetic patients when 
compared to that of no NAFLD diabetic group ( 17 vs  7)  which is statistically 
significant. (p value -0.001) 
 
 
 
 
 
   NAFLD  Total 
P 
value 
    Yes No   0.001 
RETINOPATHY Yes Count 17 7 24 
    % within Retinopathy 70.8% 29.2% 100.0% 
    % within NAFLD 42.5% 11.7% 24.0% 
  No Count 23 53 76 
    % within Retinopathy 30.3% 69.7% 100.0% 
    % within NAFLD 57.5% 88.3% 76.0% 
Total Count 40 60 100 
  % within Retinopathy 40.0% 60.0% 100.0% 
  % within NAFLD 
100.0% 
100.0
% 
100.0% 
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Chart: 6
 
Chart.6 shows the retinopathy distribution in diabetic patients having NAFLD 
and no NAFLD. 
  
PERIPHERAL NEUROPATHY 
 
Table.14 
 
    NAFLD  Total 
P 
value 
    Yes No    
 
 
 
 
< 
0.001 
Peripheral 
Neuropathy 
Yes Count 
18 0 18 
    % within Neuropathy 100.0% .0% 100.0% 
    % within NAFLD  45.0% .0% 18.0% 
  No Count 22 60 82 
    % within Neuropathy 26.8% 73.2% 100.0% 
    % within NAFLD  55.0% 100.0% 82.0% 
Total Count 40 60 100 
  % within Neuropathy 40.0% 60.0% 100.0% 
  % within NAFLD  100.0% 100.0% 100.0% 
 
Table.14 shows the peripheral neuropathy distribution in diabetic patients 
having NAFLD and no NAFLD. 
 
Out of 100 patients with diabetes 18 patients had peripheral neuropathy. Out of 
40 patients with NAFLD, 18 had peripheral neuropathy and 22 did not have 
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peripheral neuropathy. The prevalence of peripheral neuropathy among no 
NAFLD group is 0.  All 18 patients with peripheral neuropathy had NAFLD. So 
in our study the prevalence of peripheral neuropathy is high among NAFLD 
diabetic patients  when compared to that of no NAFLD diabetic group( 18 vs 0 ) 
which is statistically significant (p value -.001). 
Chart.7 
  
 
Chart.7 shows the peripheral neuropathy distribution in diabetic patients having 
NAFLD and no NAFLD. 
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Diabetic nephropathy (DN) 
 
Table.18  
 
    NAFLD Total P value 
Diabetic 
nephropathy (DN)   Yes No   
 Grade I Count 29 38 67  
 
 
0.594 
    % within DN 43.3% 56.7% 100.0% 
    % within NAFLD 72.5% 63.3% 67.0% 
  Grade II Count 11 20 31 
    % within  DN 35.5% 64.5% 100.0% 
    % within NAFLD 27.5% 33.3% 31.0% 
  Grade III Count 0 1 1 
    % within DN .0% 100.0% 100.0% 
    % within NAFLD .0% 1.7% 1.0% 
  Grade IV Count 0 1 1 
    % within  DN .0% 100.0% 100.0% 
    % within NAFLD .0% 1.7% 1.0% 
Total Count 40 60 100 
  % within DN 40.0% 60.0% 100.0% 
  % within NAFLD 100.0% 100.0% 100.0% 
 
Table.18 shows the diabetic nephropathy distribution in diabetic patients having 
NAFLD and no NAFLD 
                  Out of 100 patients with diabetes 67 patients are in grade 1 diabetic 
nephropathy, 31 patients are in grade 2 diabetic nephropathy, 1 patient is in 
grade 3 diabetic nephropathy,1 patient is grade 4 diabetic nephropathy. 
Out of 40 diabetic patients with NAFLD 29 patients are in grade 1 diabetic 
nephropathy, 11 patients are in grade 2diabetic nephropathy and there is no 
patient in grade 3 and grade 4nephropathy. 
 
 There is no co relation between NAFLD and diabetic nephropathy and it is 
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statistically insignificant. (p value-0.594) 
GFR LESS THAN 30  
 
   NAFLD Total P 
value     Yes No   
GFR < 
30 
Yes Count 
0 2 2 
0.243 
    % within < 30 .0% 100.0% 100.0% 
    % within 
NAFLD 
.0% 3.3% 2.0% 
  No Count 40 58 98 
    % within GFR 
<30 
40.8% 59.2% 100.0% 
    % within 
NAFLD 
100.0% 96.7% 98.0% 
Total Count 40 60 100 
  % within GFR 
<30 
40.0% 60.0% 100.0% 
  % within 
NAFLD 
100.0% 100.0% 100.0% 
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Out of 100 patients with diabetes only 2 had GFR less than 30.  In our study 
none of the NAFLD diabetic patients had GFR less than 30 and it is  statistically 
insignificant (p value-0.243). 
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Group Statistics 
 
  NAFLD N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
p value 
Age in years Yes 40 56.98 7.694 1.217 .062 
   No 60 54.37 6.065 .783 
Duration of 
Diabetes 
Yes 
40 4.50 2.013 .318 .107 
 
  No 60 3.82 2.087 .269 
SBP Yes 40 139.95 15.100 2.387 
.006 
  No 60 129.93 18.966 2.449 
DBP Yes 40 88.53 11.602 1.834 
.012 
  No 60 82.95 9.989 1.290 
Fasting 
sugar 
Yes 
40 115.70 34.187 5.405 .673 
 
  No 60 118.67 34.345 4.434 
Post 
Prandial 
Sugar 
Yes 
40 165.95 34.809 5.504 .988 
  No 60 165.85 33.023 4.263  
UREA Yes 40 32.63 9.080 1.436 .049 
   No 60 38.28 16.306 2.105 
Creatinine Yes 40 .880 .2441 .0386 .189 
   No 60 .983 .4514 .0583 
Triglyceride
s 
Yes 
40 182.98 40.972 6.478 
<.001 
  No 60 157.05 27.567 3.559 
Total 
Cholesterol 
Yes 
40 238.63 31.181 4.930 
.028 
  No 60 232.60 32.941 4.253 
ABI Yes 40 .916 .2161 .0342 
0.865 
  No 60 .908 .1992 .0257 
CIMT Yes 40 .789 .1961 .0310 .010 
   No 60 .698 .1489 .0192 
AST Yes 40 42.63 24.147 3.818 .115 
   No 60 37.45 6.060 .782 
ALT Yes 40 47.68 38.090 6.023 .049 
   No 60 37.80 4.804 .620 
Total 
Protein 
Yes 
40 6.9900 .41928 .06629 .684 
 
  No 60 7.0267 .45206 .05836 
Albumin Yes 40 3.9200 .42740 .06758 .389 
   No 60 4.0017 .48380 .06246 
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DISCUSSION 
Nowadays the prevalence of nonalcoholic liver disease is raising in the general 
population especially those with diabetes, metabolic syndrome, and obese 
individual. There is geographic variation in the prevalence of nonalcoholic liver 
disease. 
PREVALENCE:  
 The prevalence of nonalcoholic liver disease in the type 2 diabetic population 
in government Royapettah hospital is 40%.According to one study in type 2 
diabetes mellitus which is conducted in north India which used liver histology 
in the diagnosis of non-alcoholic liver disease, the prevalence of non-alcoholic 
liver disease was 88%,the prevalence of NASH was 63%,the prevalence of 
fibrosis was 38%
[94]
. In our study the prevalence of nonalcoholic liver disease 
was made using imaging modality as per definition of AASLD. According to 
Schwenzen et al the sensitivity and specificity of ultrasound in making the 
diagnosis of nonalcoholic liver disease was up to 94%and upto 95% 
respectively 
[95]
.  According to the study conducted by Browning J et al 
diabetic patients concomitantly had NAFLD upto 45% of the cases 
[96, 97, 98]
 
According to Bellentani et al the prevalence of non-alcoholic liver disease 
among type 2 diabetes mellitus was 30 to 50% 
[99]
. 
 
93 
 
AGE AND SEX: 
 According to our study the prevalence of non-alcoholic liver disease among 
type 2 diabetes patients was high in the 50 to 60 years age group. According to 
Bellentai et al the prevalence and the severity of nonalcoholic liver disease 
increases with increasing age 
[100]. 
According to Hu X et al Older age, male 
gender are the risk factors in the development of NAFLD 
[101]
.  
According to the study conducted by Hilden m et al the prevalence of 
nonalcoholic liver disease in the individuals below 20 years was 1%, between 
20 to 40 years was 18%,and 60 and more years was 39%. 
According to our study there is no sex difference in the prevalence of 
nonalcoholic liver disease( male vs female 19 vs 21).According to the study 
conducted by Sheth et al the prevalence of nonalcoholic liver disease was high 
among women
[102]
. 
 According to the study conducted by Caruli et al the prevalence of 
nonalcoholic liver disease was high among men
[103]
.This is because female are 
protected against non-alcoholic liver disease by female sex hormones
[104]
.The 
gender difference in the prevalence of  non-alcoholic liver disease may be due 
to the difference in the distribution of fat among women
[105, 106]
. 
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BODY MASS INDEX: 
According to our study obese individuals and overweight individuals had high 
frequency of getting NAFLD when compared with that of normal weight 
individuals(11vs 9 obese individual,22vs 17 overweight individual).According 
to Jokoben M U et al the prevalence of NAFLD is high among those patients 
having high BMI and those having high waist circumference
[107]
. According to 
Dionysos study the NAFLD was present in 94% of the obese individuals, 67% 
of the overweight individual.  
According to Angulo p et al the obese individuals are having high frequency of 
getting NAFLD and will have the severe form of disease 
[108]
. According to our 
study in patients having NAFLD 55% are overweight, 27.5% are obese,15% are 
normal weight and 2.5% are under weight. According to our study the mean 
duration of diabetes in NAFLD patients is 4.5 years and those not having 
NAFLD were 3.82 years. 
According to the study conducted by Vishwanathan et al which is conducted in 
south India the mean duration of diabetes in NAFLD group was 9 years 
[109]
.  According to LvWS et al  NAFLD negatively correlated with the duration 
of diabetes
[110]
. 
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BLOOD PRESSURE:  
According to our study the patients with NAFLD had both high systolic and 
high diastolic blood pressure when compared to that of those not having 
NAFLD (systolic bp140 vs130). According to Luminita et al the prevalence of 
NAFLD was very high in the nondipper, reverse dipper, and extreme dipper 
than those who were dipper. NAFLD and hypertension are correlated because of 
insulin resistance which is involved in the pathogenesis of both the diseases. 
According to this study altered BP level is a marker of NAFLD 
[111]
. 
 According to Lv WS  et al patients  with NAFLD had greater body weight, 
fasting blood glucose (FBG), , blood pressure ,concentration than those without 
NAFLD (P < 0.05).
[110]
 
BLOOD GLUCOSE LEVELS: 
According to our study there is no correlation between blood sugar level and 
NAFLD group and the mean fasting blood glucose level of NAFLD group and 
no NAFLD group was 115.70 vs 118.67 mean postprandial blood glucose level 
of NAFLD group and no NAFLD group 165.95 vs 165.85.  
According to Jimba et al the prevalence of NAFLD is high among the 
individuals having high blood sugar in general population 
[112]
. 
According to S.Bajaj et al the diabetic patients who are having NAFLD had 
high fasting blood sugar and insulin level 
[113]
. 
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According to the study conducted by Saint Loius university, accumulation of 
fat in the liver occurs as a result of resistance to insulin in NAFLD individuals. 
In NAFLD because of resistance to insulin, body cell reacts poorly to the insulin 
which causes hyperglycemia 
[114]
. 
DYSLIPIDEMIA: 
According to our study the diabetic NAFLD patient had high total cholesterol 
and high triglycerides level than compared with no NAFLD patients which are 
statistically significant. The mean TGL and Total cholesterol were 182.98 vs 
157.05, and 238.63 vs 233.37 in NAFLD and no NAFLD patients. So 
dyslipidaemic individuals are at high risk of getting NAFLD. 
According to Chatrath H et al   NAFLD individuals often had altered lipid 
metabolism along with the characteristics of metabolic syndrome. The NAFLD 
individual usually will have increased triglycerides, ―increased LDL (nontype 
A) particles and decreased HDL‖ .The altered lipid metabolism in NAFLD is 
due to overproduction VLDL by the liver and decreased clearance of lipid by 
the liver 
[115]
. 
According to David e cohen NAFLD usually has an atherogenic lipid profile. 
The pathogenesis of atherogenic lipid profile in NAFLD is due to insulin 
resistance 
[116]
. 
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SERUM ALBUMIN LEVEL: 
 In our study the mean albumin in NAFLD and no NAFLD group was 3.92 vs 
4.00.Even though the NAFLD patients had low albumin than no NAFLD group, 
there was no statistical significance. According to Younossi ZM et al high 
bilirubin, low albumin and increased prothrombin time are the predictor‘s of 
mortality in NAFLD patients 
[117]
. 
According to Fierbinteanu-Braticevici et al  CRP, splenic longitudinal 
diameter, insulin resistance scale, GGT, INR, age, body mass index, albumin 
are correlated well with NASH. The four predictors of NASH are ―CRP 
(p=0.004), SLD (p=0.018), HOMA (p=0.03) and albumin level (p=0.041)‖.the 
albumin (p=0.008), is associated with severe fibrosis [118]. 
TRANSAMINASES LEVELS:   
In our study out of 100 patients only 3 patients had transaminase elevation. The 
elevation of ALT is statistically significant in NAFLD patients when compared 
with that of no NAFLD patients. There is no correlation between NAFLD and 
AST levels.  
A study was conducted by Ioannou et al based on 10 year risk of 
cardiovascular events by Framingham risk score (FRS) in individuals with 
elevated and normal ALT levels. The ALT is said to be elevated when it is more 
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than 43 IU/L. According to this study the elevated ALT are associated with high 
FRS score 
[119]
. 
According to a Swedish study there was increased mortality in patients with 
NAFLD who had elevated liver enzyme level. The level of enzyme in NAFLD 
patients may be normal 
[120]
.Among NAFLD individuals usually there will be 
fluctuation of liver enzymes 
[121]
. 
ALT level varies according to the severity of liver steatosis than GGT levels 
[122]
.According to Kotronen A et al the elevated level ALT correlate with 
increased cardiovascular mortality.
[123,124,125]
. According to Yun KE et al the 
correlation between ALT level and CV mortality is mainly due to insulin 
resistance, which is strong risk factor for both diseases.  
[126]
 
PERIPHERAL ARTERIAL DISEASE: 
According to our study there is no relationship between NAFLD and the 
peripheral arterial disease among diabetic paopulation. In our study the 
peripheral arterial disease was diagnosed by using Oscillometric method.  
According to AM MacDougall et al the sensitivity and the specificity of 
oscillometry in establishing the diagnosis of peripheral arterial disease was 71% 
and 89% 
[127]
.  
According to the study conducted by Yucihiro et al there is no relationship 
between NAFLD and PAD 
[128]
. This study was conducted in japan. 
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A large study conducted in south India by Vishwanathan et al found that there 
is no correlation between NAFLD and PAD among diabetic population. 
[109]
 
CAROTID INTIMAL MEDIAL THICKNESS: 
 According to our study mean carotid intimal medial thickness was high in 
patients with NAFLD than those without NAFLD. The mean CIMT between 
NAFLD and no NAFLD group was 0.789 Vs 0.698 .The no NAFLD patients 
had lower CIMT than NAFLD patients. So there is positive correlation between 
CIMT and NAFLD. 
A study in Italy conducted by Pacifico L et al in paediatric population showed 
that carotid artery intima-media thickness (IMT) was high in NAFLD obese 
children than those obese children without NAFLD and lean children 
[131]
. 
According to Vishwanathan et al there is a positive correlation between 
NAFLD and CIMT. 
[109]
. According to Yuchirio et al, NAFLD patients who are 
in advanced age had higher CIMT than those without NAFLD in diabetic 
patients. 
[128]
 
A study conducted by Targher at al showed there is correlation between the 
CIMT and the histological severity of  NAFLD  
[122]
. 
 
 
 
100 
 
ISCHEMIC HEART DISEASE: 
According to our study the prevalence of ischemic heart disease is high among 
diabetic NAFLD patients.60% of patient with ischemic heart disease had 
NAFLD. 
A study conducted in 129 patients with NAFLD in Sweden showed a high 
incidence of cardiovascular mortality in NAFLD patients when compared with 
that of general population. 
[132]
 
A study conducted in turkey by Arslan U with 92 individuals who had 
undergone coronary angiography, showed that NAFLD increased the risk of 
coronary artery disease as shown by coronary angiogram 
[133]
. 
The study conducted by Targher G et al showed   increased prevalence of IHD 
(22 % vs. 15%), CVA (17% vs. 10%) and PAD (13% vs. 7%) in people with 
type2 diabetes with NAFLD [129]. 
According to ATP 3 panel NAFLD patients had risk factors that may 
accentuate atherosclerosis. ATP 3 panel suspected that the NAFLD individuals 
are at maximum risk of getting ischemic heart disease 
[134]
. 
In United States it was found that the prevalence of obesity and metabolic 
syndrome are increasing which is a common risk factor for both NAFLD and 
ischemic heart disease 
[135-137]
. 
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The patients with NAFLD who had high degree of inflammation and fibrosis 
had elevated levels of CRP and IL6 
[138]
 .So NAFLD is considered as a chronic 
inflammatory condition which may accelerate atherosclerosis. 
The levels of adiponectin antiatherogenic cytokines are reduced in NAFLD, 
which may explain the mechanism of accelerated atherosclerosis 
[139]
. 
According to Dunn W at el who conducted study in 1000 NAFLD patients with 
the control of 6600 patients. All of them were followed for a mean duration of 9 
years. This study showed that NAFLD patients had increased mortality due to 
cardiovascular diseases mainly around the age of 50 years 
[140]  .
 
A study was conducted with type 1 diabetes mellitus by Targher G et al 
showed that there is high prevalence of cardiovascular death in the NAFLD 
patients
[141]
. 
In Verona study it was found that diabetic cirrhosis patients die mainly due 
cardiovascular complication when compared with that of general population 
(“standardized mortality ratio”=1.34) [142]. 
CEREBROVASCULAR ACCIDENT 
In our study there is positive correlation between NAFLD diabetic patients with 
Cerebrovascular accident. There is high prevalence of NAFLD in the stroke 
patients. 
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The study conducted by Targher G et al showed   increased prevalence of IHD 
(22 % vs. 15%), CVA (17% vs. 10%) and PAD (13% vs. 7%) in people with 
type2 diabetes with NAFLD [129]. 
DIABETIC NEPHROPATHY 
According to our study there is no correlation between albuminuria and NAFLD 
in the diabetic patients. The no NAFLD group had severe forms of diabetic 
nephropathy namely stage 3 and stage 4 nephropathy.  
According to the study conducted by Yucihiro et al there is no relationship 
between NAFLD and diabetic nephropathy among diabetic population 
[128]
. This 
study was conducted in japan. 
A large study conducted in south India by Vishwanathan et al found that there 
is no correlation between NAFLD and diabetic nephropathy among diabetic 
population. 
[109]
 
According to the study conducted by Hwang ST et al there is very good 
relationship between NAFLD and microalbuminuria and newly detected 
diabetes and with prediabetes 
[143] .
 
DIABETIC NEUROPATHY 
      According to our study there is a very strong correlation between NAFLD 
diabetic patients and peripheral neuropathy. In our study all patients with 
peripheral neuropathy had NAFLD. 
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According to Yuichiro Takeuchi et al there is no correlation between NAFLD 
and neuropathy 
[128]
. According to Vishwanathan et al who conducted study in 
south India there is a strong correlation between NAFLD and neuropathy 
[109]
. 
 According to study conducted by Lv WS et al negatively correlated diabetic 
retinopathy and diabetic neuropathy with NAFLD patients 
[90]
. 
DIABETIC RETINOPATHY  
According to our study there is a strong correlation between NAFLD and 
diabetic retinopathy. According to LvWS et al NAFLD negatively correlated 
with diabetic retinopathy 
[110]
. According to Targher G, Bertolini L  who 
conducted studies in type 1 diabetes mellitus, diabetic NAFLD patients had high 
prevalence of CKD and retinopathy 
[145]
. 
According to Yuichiro Takeuchi et al there is no correlation between NAFLD 
and retinopathy 
[128]
. According to Vishwanathan et al who conducted study in 
south India there is strong correlation between NAFLD and retinopathy.
[109]
. 
According to study conducted in type 2 diabetes mellitus by Targher 
G, Bertolini L et al the prevalence of chronic kidney disease and diabetic 
retinopathy is high among NAFLD individuals 
[144]
. 
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LIMITATIONS OF THE STUDY 
1. Sample size was small so further studies with bigger sample size has to 
be done to further verify the results. 
2. Our study has been done among the population attending Government 
Royapettah hospital OPD and there can be a bias in selecting such a 
group of population, so this study has to be done among the general 
population or it has been done at multiple centers and meta-analysis of 
those studies can provide a significant conclusion of this issue. 
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CONCLUSION 
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CONCLUSION 
1. The diabetic patients with nonalcoholic liver disease are mostly 
overweight and obese. 
2. The diabetic patients with nonalcoholic liver disease are mostly in 
the age group of 50 to 60 years of age. 
3. The diabetic patients with nonalcoholic liver disease have high 
triglyceride level and high total cholesterol level. 
4. The diabetic patients with nonalcoholic liver disease have both high 
systolic and diastolic blood pressure. 
5. The diabetic patients with nonalcoholic liver disease had high 
prevalence of ischemic heart disease. 
6. The diabetic patients with nonalcoholic liver disease had high 
prevalence of diabetic retinopathy. 
7. The diabetic patients with nonalcoholic liver disease had high 
prevalence of diabetic peripheral neuropathy. 
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8. The diabetic patients with nonalcoholic liver disease had a high 
prevalence of cerebrovascular accident and have increased carotid 
intimal medial thickness. 
9. The diabetic patients with nonalcoholic liver disease did not  have 
any relation with diabetic nephropathy and peripheral arterial disease. 
Thus NAFLD in type 2 diabetes mellitus independently predicts 
of diabetic microangiopathy and diabetic macroangiopathy and 
the characteristics of NAFLD in type 2 diabetes mellitus are 
studied. 
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ABBREVIATIONS 
NAFLD     Nonalcoholic Fatty Liver Disease 
CKD       Chronic Kidney Disease 
ACR        Albumin Creatinine Ratio 
CIMT      Carotid Intimal Medial Thickness 
IHD        Ischemic Heart Disease 
CVA      Cerebrovascular Accident 
BMI      Body Mass Index 
PAD       Peripheral Arterial Disease 
DN         Diabetic Nephropathy 
DR         Diabetic Retinopathy 
TGL        Triglycerides 
ABI       Ankle Brachial Index 
ATP 3    Adult Treatment Panel 3 
GFR       Glomerular Filtration Rate 
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PROFORMA 
 
NAME:       
AGE:  
SEX: 
ADDRESS:        
 
HISTORY: 
h/o of bilateral spontaneous pain, hypoesthesia Paraesthesia 
h/o of previous myocardial infarction 
h/o systemic hypertension 
h/o chronic kidney disease 
h/o of stroke 
h/o medication use 
h/o viral hepatitis , jaundice, liver disease 
h/o bariatric surgery 
h/o TPN 
h/o alcohol consumption /drinking pattern 
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EXAMINATION  
HEIGHT: 
WEIGHT: 
BMI: 
 
BLOOD PRESSURE:                          PULSE RATE: 
RECORDINGS 1
ST
 READING 2
ND
 READING 
SITTING   
SUPINE   
STANDING   
 
GENERAL EXAMINATION 
CVS: 
RS: 
P/A: 
CNS: 
1. TENDON REFLEX 
2. VIBRATION SENSATIONS 
3. FUNDUS EXAMINATION 
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INVESTIGATION 
 
1. Blood glucose –fasting postprandial 
2. Lipid profile 
3. Liver function test with enzymes 
4. Ultrasonogram 
5. Urine spot albumin creatinine ratio 
6. ECG 
7. Carotid Doppler –Carotid Intimal Thickness 
8. Ankle Brachial Index (oscillometric method ) 
 
 
 
 
 
 
 
 
Signature of Investigator                                             Signature of Guide  
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÷{õ¯õÎ J¨¦uÀ £iÁ® 
Bµõ´a]°ß ÂÁµ®:  
Bµõ´a] ø©¯®: Aµ_ RÌ£õUP® ©¸zxÁU PÀ¿¶ ©¸zxÁ©øÚ 
÷{õ¯õÎ°ß ö£¯º:      ÷{õ¯õÎ°ß Á¯x: 
£vÄ Gs: 
 1. ÷©ØSÔ¨¤mkÒÍ Bµõ´a]°ß ÷{õUPzøu²® £¯øÚ²® ¬ÊÁx©õP 
¦¶¢xöPõs÷hß. ÷©¾® GÚx AøÚzx \¢÷uP[PøÍ²® ÷Pmk 
AuØPõÚ ÂÍUP[PøÍ²® öuÎÄ£kzvU öPõs÷hß. 
 
2. ÷©¾® C¢u Bµõ´a]US GÚx ö\õ¢u Â¸¨£zvß ÷£¶À £[÷PØQ÷Óß 
GßÖ®, ÷©¾® G¢u ÷{µzv¾® GÆÂu ¬ßÚÔÂ¨¦ªßÔ C¢u 
Bµõ´a]°¼¸¢x Â»P ¬Êø©¯õÚ E¶ø© EÒÍøu²®, CuØS GÆÂu 
\mh ¤øn¨¦® CÀø» Gß£øu²® AÔ÷Áß. 
 
3. Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõ÷µõ, Bµõ´a] 
÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ G¨÷£õx 
÷Ásk©õÚõ¾® GÚx AÝ©v°ßÔ GÚx EÒ÷{õ¯õÎ £vÄPøÍ C¢u 
Bµõ´a]UPõP÷Áõ AÀ»x GvºPõ» ¤Ó Bµõ´a]PÐUPõP÷Áõ 
£¯ß£kzvUöPõÒÍ»õ® GßÖ® ÷©¾® C¢u |£¢uøÚ {õß 
CÆÁµõ´a]°¼¸¢x Â»QÚõ¾® uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® 
GÚx Aøh¯õÍ® \®£¢u¨£mh G¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒ 
uÂµ) öÁÎ°h¨£h©õmhx GßÓ EÖvö©õÈ°ß ö£¯¶À C¢u 
Bµõ´a]°¼¸¢x QøhUP¨ö£Ö® ¬iÄPøÍ öÁÎ°h ©Ö¨¦ 
öuÔÂUP©õm÷hß GßÖ EÖv¯ÎUQß÷Óß. 
 
   
4. C¢u Bµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷Óß GßÖ® ÷©¾® 
Bµõ´a]U SÊÂÚº GÚUS AÎUS® AÔÄøµPøÍ uÁÓõx ¤ß£ØÖ÷Áß 
GßÖ® EÖv¯ÎUQß÷Óß. 
 
5. C¢u Bµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨ £¶÷\õuøÚPÐUS® 
JzxøÇ¨¦ u¸÷Áß GßÖ EÖv¯ÎUQß÷Óß. 
 
 6. C¢u Bµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u Â¸¨£zvß 
÷£¶¾® _¯AÔÄhÝ® ¬Ê©ÚxhÝ® \®©zvUQß÷Óß GßÖ Cuß -»® 
J¨¦UöPõÒQ÷Óß. 
 
÷{õ¯õÎ°ß øPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP 
Ch®:     ÷uv: 
Bµõ´a]¯õÍ¶ß øPö¯õ¨£® 
Ch®:     ÷uv: 
 
 
